INTRODUCTION:
Spleen is an unusual site of metastasis. and is usually a sign of
extensive disease. Splenic metastases from solid tumors, like colon
cancers, are considered exceptional (1). The most common
primary sources of splenic metastasis in cases of multi -visceral cancer
are breast, lung, colorectal, melanoma and ovarian carcinomas and
colorectal and ovarian carcinomas in cases of solitary splenic lesion
(2,3). Berge reported that the incidence of splenic metastasis from
colon and rectal carcinomas as 4.4% and 1.6%, respectively (4).
It is still uncertain whether the rarity of splenic metastasis is due to
the splenic immunological functions or the characteristic splenic
anatomical position and its bloodstream state. The rarity of splenic
metastasis from other organs may be due to the histological peculiarity
of splenic sinusoidal architecture and the absence of splenic afferent
lymphatics (5). The prevalence of splenic metastasis, although very low,
is increasing nowadays with the improvement of imaging technology (6).
Studies have shown that splenectomy followed by adjuvant chemotherapy
can improve survival in patients with spleen metastasis from colorectal
cancer (7).When left untreated , spleen metastasis can lead to the
rupture of the spleen, which can be life threatening. Interval survival
following splenectomy ranged from 3 to 84 months, with a mean of 22.5
months (6).It was found that patients who received adjuvant chemotherapy
after splenectomy had better survival rates than those who did not.
This case report has been reported according to the SCARE 2020
guidelines (8).